TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Nursing Intervention to Prevent Poor Psychosocial Outcomes in Living Donors
Brief Summary: The purpose of this study is to evaluate the potential effectiveness of a psychosocial intervention based on the principles of motivational interviewing. The novel intervention will assist living donor candidates to think through any remaining concerns or questions that they may have about living donation. If the intervention is effective, it may help to prevent post-donation problems related to psychological and health outcomes.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reception staff providing handout., Behavioral: Mobile Tablet (e.g. iPad) | Intervention Type: BEHAVIORAL; Name: Reception staff providing handout.; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Mobile Tablet (e.g. iPad); Assigned to Arm(s): Intervention
B: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Website Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Website Intervention | Intervention Type: BEHAVIORAL; Name: Website Intervention; Assigned to Arm(s): Website Intervention
C: Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: video | Intervention Type: BEHAVIORAL; Name: video; Assigned to Arm(s): 1
D: Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Lifestyles Education | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyles Education; Assigned to Arm(s): Enhanced Standard Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to assess whether 4-months of interval-walking exercise training improves glycemic control in individuals with type 2 diabetes mellitus. The effects of interval-walking training will be compared to continuous-walking exercise in a randomised, controlled trial design. Changes in glycemic control will be examined using oral glucose tolerance tests (OGTT) with stable isotope methodology. In addition, insulin sensitivity and secretion will be examined using glucose clamps combined with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise - Continuous Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise - Continuous Walking | Arm Label: Exercise - Interval Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Training - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise Training - Interval Walking; Assigned to Arm(s): Exercise - Interval Walking | Intervention Type: BEHAVIORAL; Name: Exercise - Continuous Walking; Assigned to Arm(s): Exercise - Continuous Walking
B: Arm Label: The experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Group walking and group educational workshops | Arm Label: The control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group walking and group educational workshops; Assigned to Arm(s): The experimental group
C: Arm Label: Physical, social and cultural activities; Type: EXPERIMENTAL; Interventions: Behavioral: Physical, social and cultural activities | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical, social and cultural activities; Assigned to Arm(s): Physical, social and cultural activities
D: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Study of Hypoxia-Stressed Bone Marrow Mononuclear Cell Intracoronary Transplantation in Myocardial Infarction and Other Heart Diseases.
Brief Summary: The purpose of this study, is to determine the differences of clinical outcomes between hypoxic pre-treatment group and control group in bone marrow stem cell transplantation (BM-SCT) to treat acute myocardial infarction (AMI); and to evaluate the safety of both treatments. Heart failure patients underwent PCI treatment after AMI and with informed consent, are randomized allocation into hypoxic pre-treated BM-SCT group, normoxic pre-treated BM-SCT group, and control group. Cell resuspension is intracoronary injected into patients receiving coronary angiography, IL-6, CRP, TNF and BNP are detected; echocardiography, cardiac MRI and ECT are analyzed to evaluate heart function and alive myocardial cells. Holter's ECG monitor is employed to observe arrhythmia and embolism. We hypothesize that, by receiving hypoxic pre-treated BM-SCT, impaired heart function will be reversed in heart failure patients.


Options:
A: Intervention Type: DRUG; Name: intracoronary infusion of progenitor cells; Assigned to Arm(s): N/A
B: Arm Label: BMSCs transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Arm Label: No BMSCs transplantation; Type: SHAM_COMPARATOR; Interventions: Procedure: Hypoxia-stressed BMSCs transplantation to cure MI | Intervention Type: PROCEDURE; Name: Hypoxia-stressed BMSCs transplantation to cure MI; Assigned to Arm(s): BMSCs transplantation, No BMSCs transplantation
C: Arm Label: BMC; Type: EXPERIMENTAL; Interventions: Biological: Intracoronary infusion of enriched bone marrow-derived progenitor cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo medium supplemented with autologous serum | Intervention Type: BIOLOGICAL; Name: Intracoronary infusion of enriched bone marrow-derived progenitor cells; Assigned to Arm(s): BMC | Intervention Type: BIOLOGICAL; Name: Placebo medium supplemented with autologous serum; Assigned to Arm(s): Placebo
D: Arm Label: The treatment group; Type: EXPERIMENTAL; Interventions: Procedure: Intracoronary injection of autologous bone marrow mononuclear cells | Arm Label: the control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Intracoronary injection of autologous bone marrow mononuclear cells; Assigned to Arm(s): The treatment group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Brief Summary: The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.


Options:
A: Arm Label: Esketamine + Standard of care; Type: EXPERIMENTAL; Interventions: Drug: Esketamine, Other: Standard of Care | Arm Label: Placebo + Standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of Care | Intervention Type: DRUG; Name: Esketamine; Assigned to Arm(s): Esketamine + Standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Standard of care | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Esketamine + Standard of care, Placebo + Standard of care
B: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline
C: Arm Label: Ketamine 0.1mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 0.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Ketamine 1.0mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketamine | Arm Label: Midazolam (Active Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.1mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.2mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 0.5mg | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine 1.0mg | Intervention Type: DRUG; Name: Placebo Midazolam; Assigned to Arm(s): Midazolam (Active Placebo)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Phase. Cord Blood Serum in the Treatment of Ocular Surface Diseases
Brief Summary: Human autologous serum (AS) eye drops have been successfully used in the treatment of severe ocular surface disorders and the enhancement of corneal wound healing, due to their growth factor (GF) content. Umbilical cord serum (UCS) contains even higher GF concentrations and the objective of the study was to prove whether UCS eye drops

1. are effective in the healing of corneal epithelial defects.
2. ameliorate the painful subjective symptoms


Options:
A: Arm Label: Autologous serum -Systane; Type: OTHER; Interventions: Drug: Autologous serum - Systane | Arm Label: Systane- Autologous serum; Type: OTHER; Interventions: Drug: Systane - Autologous serum | Intervention Type: DRUG; Name: Autologous serum - Systane; Assigned to Arm(s): Autologous serum -Systane | Intervention Type: DRUG; Name: Systane - Autologous serum; Assigned to Arm(s): Systane- Autologous serum
B: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
C: Arm Label: UCB eyedrops, single arm; Type: N/A; Interventions: Other: UCS eyedrops | Intervention Type: OTHER; Name: UCS eyedrops; Assigned to Arm(s): UCB eyedrops, single arm
D: Arm Label: Severe dry eye; Type: EXPERIMENTAL; Interventions: Drug: 0.02% Fm, SH, Drug: 0.02% Fm, SH, 0.05% CsA, Other: 0.02% Fm, SH, tBCL, Drug: 0.02% Fm, SH, AS | Intervention Type: DRUG; Name: 0.02% Fm, SH; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, 0.05% CsA; Assigned to Arm(s): Severe dry eye | Intervention Type: OTHER; Name: 0.02% Fm, SH, tBCL; Assigned to Arm(s): Severe dry eye | Intervention Type: DRUG; Name: 0.02% Fm, SH, AS; Assigned to Arm(s): Severe dry eye

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Brief Summary: Fibromyalgia is a condition of chronic widespread pain, sleep disturbance and fatigue. Most of the patients with fibromyalgia complain of either non-restorative sleep or complaints of disturbed sleep due to pain. The study aimed at examining the effects of milnacipran on sleep disturbance in patients with fibromyalgia. The study is a randomized, double-blind, placebo controlled, two way crossover polysomnography (PSG) study to explore the effects of milnacipran on sleep disturbance. Patients received either milnacipran 50 mg twice a day (BID) or matching placebo.


Options:
A: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)
B: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 4; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: [S,S]-Reboxetine | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: [S,S]-Reboxetine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Brief Summary: Fibromyalgia is a condition of chronic widespread pain, sleep disturbance and fatigue. Most of the patients with fibromyalgia complain of either non-restorative sleep or complaints of disturbed sleep due to pain. The study aimed at examining the effects of milnacipran on sleep disturbance in patients with fibromyalgia. The study is a randomized, double-blind, placebo controlled, two way crossover polysomnography (PSG) study to explore the effects of milnacipran on sleep disturbance. Patients received either milnacipran 50 mg twice a day (BID) or matching placebo.


Options:
A: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + CBT-I | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT-I plus placebo antidepressant medication | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram + CBT-I; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT-I plus placebo antidepressant medication; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 3
D: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Brief Summary: Fibromyalgia is a condition of chronic widespread pain, sleep disturbance and fatigue. Most of the patients with fibromyalgia complain of either non-restorative sleep or complaints of disturbed sleep due to pain. The study aimed at examining the effects of milnacipran on sleep disturbance in patients with fibromyalgia. The study is a randomized, double-blind, placebo controlled, two way crossover polysomnography (PSG) study to explore the effects of milnacipran on sleep disturbance. Patients received either milnacipran 50 mg twice a day (BID) or matching placebo.


Options:
A: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran
C: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
D: Arm Label: Patients taking the drug Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Patients taking the placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Patients taking the drug Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Patients taking the placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Aerobic Training During Hemodialysis on Exercise Tolerance in End Stage Renal Disease Patients
Brief Summary: The investigators raised the hypothesis that exercise training would be associated with improvement in exercise tolerance and VO2 kinetics in hemodialysis patients.


Options:
A: Arm Label: Standard Dialysis; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Typical Dialysis, Procedure: Exercise | Arm Label: Cold Dialysis; Type: EXPERIMENTAL; Interventions: Procedure: Cold Dialysis, Procedure: Exercise | Intervention Type: PROCEDURE; Name: Cold Dialysis; Assigned to Arm(s): Cold Dialysis | Intervention Type: PROCEDURE; Name: Typical Dialysis; Assigned to Arm(s): Standard Dialysis | Intervention Type: PROCEDURE; Name: Exercise; Assigned to Arm(s): Cold Dialysis, Standard Dialysis
B: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Novel Approach to MRSA Screening of Colonized Patients and Impact on Hospital Resource Allocation and Patient Care
Brief Summary: Methicillin-resistant Staphylococcus aureus (MRSA) is endemic in hospital settings. Colonization with MRSA puts patients at increased risk for invasive infections, and MRSA infections have been associated with high costs and adverse clinic outcomes. Patients can clear MRSA spontaneously. Improved approaches for identifying patients who are no longer colonized are needed; we hypothesize that more sensitive nucleic acid amplification can be used to improve identification of patients who are no longer colonized.


Options:
A: Intervention Type: PROCEDURE; Name: Intensive Control Strategy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Standard Control Strategy; Assigned to Arm(s): N/A
B: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group
C: Intervention Type: PROCEDURE; Name: Reinforced isolation + Muciprocine; Assigned to Arm(s): N/A
D: Arm Label: Active Screening; Type: OTHER; Interventions: Device: nucleic acid amplification of nasal swab; nasal swab culture | Arm Label: Passive Screening; Type: OTHER; Interventions: Other: Nasal swab culture | Intervention Type: DEVICE; Name: nucleic acid amplification of nasal swab; nasal swab culture; Assigned to Arm(s): Active Screening | Intervention Type: OTHER; Name: Nasal swab culture; Assigned to Arm(s): Passive Screening

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Comparative Efficacy and Safety Trial of Intravenous Solutions for the Treatment of Moderate to Severe Dehydration in Children With Acute Gastroenteritis
Brief Summary: The primary objective of this study is to compare the efficacy and safety of the use of a multiple electrolyte solution to the use of saline for the treatment of moderate to severe dehydration due to acute gastroenteritis (AGE) in children.


Options:
A: Arm Label: multiple electrolyte solution; Type: EXPERIMENTAL; Interventions: Drug: multiple electrolyte solution | Arm Label: saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: multiple electrolyte solution; Assigned to Arm(s): multiple electrolyte solution | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
B: Arm Label: Intravenous fluids; Type: OTHER; Interventions: Drug: Lower chloride fluids (Hartmann's solution and Plasmalyte®) | Intervention Type: DRUG; Name: Lower chloride fluids (Hartmann's solution and Plasmalyte®); Assigned to Arm(s): Intravenous fluids
C: Arm Label: Phase A1: Plasmalyte; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloid | Arm Label: Phase A2: 0.9% Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Crystalloid | Arm Label: Phase B1: PlasmaVolume; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colloid | Arm Label: Phase B2: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colloid | Intervention Type: DRUG; Name: Crystalloid; Assigned to Arm(s): Phase A1: Plasmalyte, Phase A2: 0.9% Saline | Intervention Type: DRUG; Name: Colloid; Assigned to Arm(s): Phase B1: PlasmaVolume, Phase B2: Voluven
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: use of a non balced fluid and of a macromolecular fluid | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: use of balanced crystalloids fluid and macromolecular fluid | Intervention Type: DRUG; Name: use of a non balced fluid and of a macromolecular fluid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: use of balanced crystalloids fluid and macromolecular fluid; Assigned to Arm(s): 2

Answer: A